NCT00426205View on ClinicalTrials.gov

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2009

Conditions
Myelodysplastic Syndrome RAEB-I or RAEB-IIRefractory Acute Myeloid LeukemiaRefractory CML Myeloid Blast Crisis
Interventions
BIOLOGICAL

GM-CSF secreting leukemia vaccine

Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00426205 - GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies | Biotech Hunter | Biotech Hunter